Mielgo-Rubio, X.; Montemuiño, S.; Jiménez, U.; Luna, J.; Cardeña, A.; Mezquita, L.; MartÃn, M.; Couñago, F.
Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy. Cancers 2021, 13, 4811.
https://doi.org/10.3390/cancers13194811
AMA Style
Mielgo-Rubio X, Montemuiño S, Jiménez U, Luna J, Cardeña A, Mezquita L, MartÃn M, Couñago F.
Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy. Cancers. 2021; 13(19):4811.
https://doi.org/10.3390/cancers13194811
Chicago/Turabian Style
Mielgo-Rubio, Xabier, Sara Montemuiño, Unai Jiménez, Javier Luna, Ana Cardeña, Laura Mezquita, Margarita MartÃn, and Felipe Couñago.
2021. "Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy" Cancers 13, no. 19: 4811.
https://doi.org/10.3390/cancers13194811
APA Style
Mielgo-Rubio, X., Montemuiño, S., Jiménez, U., Luna, J., Cardeña, A., Mezquita, L., MartÃn, M., & Couñago, F.
(2021). Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy. Cancers, 13(19), 4811.
https://doi.org/10.3390/cancers13194811